Kalman Emry Wijaya
Head of Market Access at Versantis AG- Claim this Profile
Click to upgrade to our gold package
for the full feature experience.
-
English Native or bilingual proficiency
-
Indonesian Native or bilingual proficiency
-
German Elementary proficiency
-
Mandarin Limited working proficiency
Topline Score
Bio
Nancy Sun
It has been my pleasure to collaborate with Kalman E. Wijaya on the ISPOR Educational Forum held during ISPOR 18th Annual European Congress in Milan, Italy. Kalman brought in expert speakers which made the forum the most satisfactory as judged by the participants. His collaboration with the ISPOR team was critical to the success of the event. Kalman is highly professional, knowledgeable and market savvy which are essential for raising the quality of any project. Also a great team leader and player who initiates creative ideas, plans and collaborates with team members to make sure projects are well done. I consider Kalman a smart and dedicated professional who could bring successes to any company.
Elvin H.
Having been knowing Kalman Wijaya for almost 14 years, all I can say about this person is that he is truly a natural-born leader. He's a loyal individual with sky-high ambitions. He is fully committed to what he does and he does it well. He is a great team player and remarkably reliable in flying solo. We have co-founded an Indonesian Biotechnology Student Forum together and during our time working side-by-side on projects, he taught me many things on how to deal with people and handle issues in crunch time. He is definitely a great get for any organizations out there.
Nancy Sun
It has been my pleasure to collaborate with Kalman E. Wijaya on the ISPOR Educational Forum held during ISPOR 18th Annual European Congress in Milan, Italy. Kalman brought in expert speakers which made the forum the most satisfactory as judged by the participants. His collaboration with the ISPOR team was critical to the success of the event. Kalman is highly professional, knowledgeable and market savvy which are essential for raising the quality of any project. Also a great team leader and player who initiates creative ideas, plans and collaborates with team members to make sure projects are well done. I consider Kalman a smart and dedicated professional who could bring successes to any company.
Elvin H.
Having been knowing Kalman Wijaya for almost 14 years, all I can say about this person is that he is truly a natural-born leader. He's a loyal individual with sky-high ambitions. He is fully committed to what he does and he does it well. He is a great team player and remarkably reliable in flying solo. We have co-founded an Indonesian Biotechnology Student Forum together and during our time working side-by-side on projects, he taught me many things on how to deal with people and handle issues in crunch time. He is definitely a great get for any organizations out there.
Nancy Sun
It has been my pleasure to collaborate with Kalman E. Wijaya on the ISPOR Educational Forum held during ISPOR 18th Annual European Congress in Milan, Italy. Kalman brought in expert speakers which made the forum the most satisfactory as judged by the participants. His collaboration with the ISPOR team was critical to the success of the event. Kalman is highly professional, knowledgeable and market savvy which are essential for raising the quality of any project. Also a great team leader and player who initiates creative ideas, plans and collaborates with team members to make sure projects are well done. I consider Kalman a smart and dedicated professional who could bring successes to any company.
Elvin H.
Having been knowing Kalman Wijaya for almost 14 years, all I can say about this person is that he is truly a natural-born leader. He's a loyal individual with sky-high ambitions. He is fully committed to what he does and he does it well. He is a great team player and remarkably reliable in flying solo. We have co-founded an Indonesian Biotechnology Student Forum together and during our time working side-by-side on projects, he taught me many things on how to deal with people and handle issues in crunch time. He is definitely a great get for any organizations out there.
Nancy Sun
It has been my pleasure to collaborate with Kalman E. Wijaya on the ISPOR Educational Forum held during ISPOR 18th Annual European Congress in Milan, Italy. Kalman brought in expert speakers which made the forum the most satisfactory as judged by the participants. His collaboration with the ISPOR team was critical to the success of the event. Kalman is highly professional, knowledgeable and market savvy which are essential for raising the quality of any project. Also a great team leader and player who initiates creative ideas, plans and collaborates with team members to make sure projects are well done. I consider Kalman a smart and dedicated professional who could bring successes to any company.
Elvin H.
Having been knowing Kalman Wijaya for almost 14 years, all I can say about this person is that he is truly a natural-born leader. He's a loyal individual with sky-high ambitions. He is fully committed to what he does and he does it well. He is a great team player and remarkably reliable in flying solo. We have co-founded an Indonesian Biotechnology Student Forum together and during our time working side-by-side on projects, he taught me many things on how to deal with people and handle issues in crunch time. He is definitely a great get for any organizations out there.
Experience
-
Versantis
-
Switzerland
-
Pharmaceutical Manufacturing
-
1 - 100 Employee
-
Head of Market Access
-
2022 - Present
-
-
-
MSD
-
United States
-
Pharmaceutical Manufacturing
-
700 & Above Employee
-
Global Assoc. Director GCI Payer, Value, Access - Market Access Oncology
-
2020 - 2021
Annual budget: USD 6 million, business impact: USD 18 billion• Leading pricing and access activities for new indication launches in immuno-oncology • Developing access strategies for pipeline products in oncology • Conducting research in oncology life-cycle management, focusing on co-formulations, new formulations beyond IV and site of care strategies• Gathering biomarker access and reimbursement payer intelligence across key markets globally, including contracting options and affordability solutions• Creating policy position papers on value of biomarkers in collaboration with policy and biomarker team
-
-
-
Philip Morris International
-
Switzerland
-
Tobacco Manufacturing
-
700 & Above Employee
-
Global Fiscal Affairs Manager
-
2019 - 2020
Annual budget: USD 1.5 million; business impact: USD 180 million• Led global health economics strategy and health economics modeling for Risk-Reduced Products (RRP)• Developed RRP fiscal strategies for future PMI products and prepared position papers accordingly• Managed global RRP taxation data and performed global fiscal and economic impact analysis• Liaised with health economists, public health and health policy experts • Built organizational capacity and capability in health economics and health policy
-
-
-
Abbott
-
United States
-
Hospitals and Health Care
-
700 & Above Employee
-
Global Market Access and Policy Senior Manager
-
2015 - 2019
Annual budget: USD 0.5Mio; business impact: USD 100 million• Created and implemented a market access policy plan across therapeutic areas, identified impact on quarterly and annual budgets• Developed Multi-Criteria Decision Analysis (MCDA) for off-patent pharmaceuticals • Promoted value-based pricing to minimize price cuts and tender losses resulting from generic equivalency • Led and executed annual market access policy strategic plan and key value policy messages. Developed Evidence Framework for Off-Patent Pharmaceuticals • Provided market access policy recommendations for portfolio expansion projects and product launches. Supported affiliates’ market access heads in local policy engagement
-
-
-
Boehringer Ingelheim
-
Germany
-
Pharmaceutical Manufacturing
-
700 & Above Employee
-
Senior Manager of Market Access, Pricing, Outcome Research and Public Affairs
-
2013 - 2015
Global Corporate role: Business impact: USD 18 million• Ensured product launches in EM (oncology, respiratory, metabolism) in pricing and payer value tools• Established partnerships with academics and policy makers in EM on Risk-Sharing Agreement and Medicine Tax white paper to promote access and affordability for patients • Expanded unconventional access to medication in emerging markets via private insurance and financing platforms (pilot on micro-financing in India and credit card financing programs in Colombia and Indonesia). Affiliate role: Annual budget: USD 1 million; business impact: USD 40 million• Led engagement with stakeholders (MoH, MoF, Private health Insurance, payers) to gain reimbursement• Created local HE study for Dabigatran as a local negotiations tool• Developed international communications platform to share best practice on health economic issues (Indonesia, - Australia/PBS-CHERE, UK-NICE/York University)• Responsible for media contacts on product launches and company profile• Managed Market Access team including Market Access Manager
-
-
-
Novartis
-
Switzerland
-
Pharmaceutical Manufacturing
-
700 & Above Employee
-
Pricing and Market Access Manager
-
2011 - 2013
Budget impact: USD 180 million• Defined pricing strategy for all Novartis Indonesia General Medicine products • Set up product launch committee on Lucentis (ranibizumab), Xolair (omalizumab).• Assigned to Asia Pacific Commercial in Singapore regional office as part of work enrichment program.• Managed Market Access team, including two Pricing and Market Access professionals• Established diploma program in collaboration with Harvard Medical School and Universitas Indonesia Budget impact: USD 180 million• Defined pricing strategy for all Novartis Indonesia General Medicine products • Set up product launch committee on Lucentis (ranibizumab), Xolair (omalizumab).• Assigned to Asia Pacific Commercial in Singapore regional office as part of work enrichment program.• Managed Market Access team, including two Pricing and Market Access professionals• Established diploma program in collaboration with Harvard Medical School and Universitas Indonesia
-
-
-
Pfizer
-
United States
-
Pharmaceutical Manufacturing
-
700 & Above Employee
-
Key Account Executive
-
2010 - 2011
Explored and developed the new model of the Pfizer-Prescription medicines business in Key Accounts (Institution, Government, and main Private Hospital), leading to 15 additional new partnered accounts for Pfizer Indonesia. Explored and developed the new model of the Pfizer-Prescription medicines business in Key Accounts (Institution, Government, and main Private Hospital), leading to 15 additional new partnered accounts for Pfizer Indonesia.
-
-
-
GSK
-
United Kingdom
-
Pharmaceutical Manufacturing
-
700 & Above Employee
-
Management Trainee
-
Jan 2010 - Mar 2010
Traineeship for three months in Consumer Healthcare Division of GSK Indonesia which focused on sales, and marketing. Traineeship for three months in Consumer Healthcare Division of GSK Indonesia which focused on sales, and marketing.
-
-
-
Sanofi
-
France
-
Pharmaceutical Manufacturing
-
700 & Above Employee
-
Intern- Quality Assurance
-
Jan 2009 - Mar 2009
Updating product database according to ASEAN Common Technical Dossier (ACTD) and its quality assurance compliance. Updating product database according to ASEAN Common Technical Dossier (ACTD) and its quality assurance compliance.
-
-
Education
-
-
Harvard Medical School
Diploma, Medicine Policy Decision Making in Health and Insurance System of Health and Policy -
-
WHU – Otto Beisheim School of Management
Master of Business and Administration (MBA) -
-
University of Liverpool
Diploma, Health Economics & Modelling -
-
University of Indonesia
Diploma, Health Economics and Health Policy -
-
Institut Teknologi Bandung
Pharmacist, Pharmacy -
-
Institut Teknologi Bandung
Graduate, Pharmacy
Community
